Serum microRNA155 is increased in patients with acute graft-versus-host disease

Clinical Transplantation

Volumn 28, Issue 3, 2014, Pages 314-323

  Xie, Lin Na ^a   Zhou, Fang ^a   Liu, Xi Min ^a   Fang, Yuan ^a   Yu, Zhe ^a   Song, Ning Xia ^a   Kong, Fan Sheng ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Allogeneic peripheral blood stem cell transplantation; Biomarker; Graft versus host disease; IL 17; IL 9; Serum microRNA

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 9; METHOTREXATE; MICRORNA; MICRORNA 155; MICRORNA 214; MICRORNA 326; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; YOUNG ADULT;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BIOMARKER; GRAFT-VERSUS-HOST DISEASE; IL-17; IL-9; SERUM MICRORNA;

ACUTE DISEASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHRONIC DISEASE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 84895925769     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12314     Document Type: Article

References (37)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009: 373: 1550.
2. Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012: 18(1 Suppl): S116.
3. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008: 9: 102.
4. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993: 75: 855.
5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993: 75: 843.
6. Harris A, Krams SM, Martinez OM. MicroRNAs as immune regulators: implications for transplantation. Am J Transplant 2010: 10: 713.
7. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 2007: 104: 7080.
8. Wu H, Neilson JR, Kumar P et al. miRNA profiling of naive, effector and memory CD8 T cells. PLoS ONE 2007: 2: e1020.
9. Neilson JR, Zheng GX, Burge CB, Sharp PA. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev 2007: 21: 578.
10. Koralov SB, Muljo SA, Galler GR et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008: 132: 860.
11. Xiao C, Srinivasan L, Calado DP et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008: 9: 405.
12. Ventura A, Young AG, Winslow MM et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008: 132: 875.
13. Xiao C, Calado DP, Galler G et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007: 131: 146.
14. Li QJ, Chau J, Ebert PJ et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007: 129: 147.
15. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009: 182: 2578.
16. Rodriguez A, Vigorito E, Clare S et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007: 316: 608.
17. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009: 136: 26.
18. Anglicheau D, Sharma VK, Ding R et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009: 106: 5330.
19. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825.
20. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974: 18: 295.
21. Ji J, Zhao L, Budhu A et al. Let-7 g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 2010: 52: 690.
22. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007: 23: 175.
23. Ambros V. The functions of animal microRNAs. Nature 2004: 431: 350.
24. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008: 105: 10513.
25. Gilad S, Meiri E, Yogev Y et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008: 3: e3148.
26. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010: 127: 118.
27. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008: 18: 997.
28. Moschos SA, Williams AE, Perry MM, Birrell MA, Belvisi MG, Lindsay MA. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. BMC Genomics 2007: 8: 240.
29. Kappel LW, Goldberg GL, King CG et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009: 113: 945.
30. Thai TH, Calado DP, Casola S et al. Regulation of the germinal center response by microRNA-155. Science 2007: 316: 604.
31. Foley JE, Jung U, Miera A et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 2005: 175: 5732.
32. Ranganathan P, Heaphy CE, Costinean S et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012: 119: 4786.
33. Efebera Y, Ranganathan P, Yu XY et al. Serum microRNAS signatures in acute graft versus host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Haematologica (18th Congress of the EHA), 2013;98(S1):P882.
34. Couturier M, Lamarthee B, Arbez J et al. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. Leukemia 2013: 27: 1527.
35. + T cells and implications for autoimmunity. J Neuroimmune Pharmacol 2010: 5: 198.
36. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci 2012: 1247: 56.
37. Fabrega E, Lopez-Hoyos M, San Segundo D et al. Serum levels of interleukin-9 during acute rejection in liver transplantation. Transplant Proc 2012: 44: 1533.